Table 132Interactions among risk factors for SCC and BCC among the PUVA-treated cohort

ReferenceMultivariate adjusted risk estimate
SCCBCC
Ionising radiation and tar (person counts)
STERN1984AYes: χ2 = 4.72; p<0.05-
Skin type and PUVA dose (person counts)
STERN1988APUVA doseSkin typeNearly identical risk for high vs low dose PUVA in skin type I–II and III–VI groups

=Increase in RR vs that expected in general population is ~2.5-fold higher for skin type I–II vs types III and IV with comparable PUVA exposure
I–IIIII–VI
<1601.01.0
160–1996.14.4
200–2597.74.7
260+11.213.2
CSA exposure and PUVA dose (unclear tumour counting)
MARCIL2001≥200 PUVA treatments (before first CSA or up to 1992 for non-users)
Non-user1.0
CSA user3.5 (2.9–4.2)
≤200 PUVA treatments (before first CSA or up to 1992 for non-users)
Non-user1.0
CSA user1.2 (0.7–2.2)
No CSA and ≤200 PUVA treatments1.0
CSA and ≥200 PUVA treatments9.1 (7.4–11.3)
Tar/UVB exposure and PUVA dose (population counts)
STERN2002Genital tumours
Low PUVA(a), low tar/UVB(b)1
Medium PUVA, high tar/UVB8.8 (0.9–85.1)
High PUVA, high tar/UVB4.5 (1.3–16.1)
Retinoid use and tar/UVB exposure (total counts)
NIJSTEN2003High tar and/or UVB(b)2.42 (2.00–2.93)High tar and/or UVB(b)3.34 (2.32–4.79)
Retinoid use and ionising radiation exposure (total counts)
NIJSTEN2003Ionising radiation vs none3.17 (2.06–4.89)Ionising radiation vs none
8.42 (4.51–15.73)
Retinoid use and PUVA exposure (total counts)
NIJSTEN2003< 2001< 2001
200–4993.36 (2.34–4.85)200–4991.17 (0.78–1.78)
>4997.26 (4.91–10.75)>4992.65 (1.62–4.36)
a

Dose classification as high, medium or low was based on number of exposures and duration of treatment (i.e., a higher cumulative dose was required to classify as high dose at later follow-up times; see full classification table in Appendix Q)

b

High tar: topical tar for >44 months; high UVB: >300 treatments

From: 9, Phototherapy

Cover of Psoriasis
Psoriasis: Assessment and Management of Psoriasis.
NICE Clinical Guidelines, No. 153.
National Clinical Guideline Centre (UK).
Copyright © National Clinical Guideline Centre - October 2012.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.